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1. Introduction
Over 64000 new renal-cell carcinomas (RCC) are annually detected in the United States, and
13000 people will die from the disease. Most RCC are discovered incidentally on medical
imaging and a great percentage of them may be treated by surgery, but one third of patients
will present either with locally advanced tumor or with metastases[1]. In addition, another
third of patients may develop metastatic disease after initial treatment.
In cancer patients imaging techniques are essential in three aspects. First, at the time of diag‐
nosis and the extension study. Ultrasonography, computed tomography (CT) and magnetic
resonance imaging (MRI) are currently available to evaluate renal masses.
Second,  since  most  RCC are  now early-stage  disease  suitable  for  surgery  with  curative
intent, the patient is candidate to follow-up during years. Early detection of recurrence is
vital, because single-organ disease may be trated by metastasectomy. Again, CT and MRI
are essential  in this  setting.  Also,  these imaging modalities  are useful  to follow-up peo‐
ple with increased susceptibility for RCC, since we have tools to identify at least a sub‐
set of these patients.
And third, imaging techniques are fundamental to evaluate the response to treatment. RE‐
CIST criteria, published in 2000 and revised in 2009, has become the most widely accepted
guideline for evaluate response [2]. Although RECIST criteria have been proved as a useful
tool to asses response in solid tumors, some limitations have been noted. One of these limi‐
tations are observed in patients treated with specific targeted therapies [3].
Traditionally, RCC have been remarkably resistant to chemo- and radiotherapy. Over the last
decade, there has been an increasing knowledge about pathophysiological processes in RCC
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including oncology pathways due to a specific driver mutations: silencing von-Hippel Lindau
gene, angiogenesis alterations, evasion of apoptosis or sustained angiogenesis.These features
have enabled the emergence of a wide spectrum of novel oncology drugs that are designed to
target and interfere with specific aberrant biological pathways. Therefore, morphological crite‐
ria may not provide meaningful data in this setting and the incorporation of new imaging tech‐
niques (MRI diffusion,  perfusion CT, PET scan, etc....)  in the diagnosis of extension and
assessment of efficacy of this drugs may provide unique physiological data that can be correlat‐
ed with histopathological changes and may provide functional information.
In this chapter we will review the main techniques of radiological diagnosis and staging, the
role of new imaging techniques and we will also discuss the validity of the classical criteria
of interpretation of response.
2. Common techniques of characterization of renal lesions
2.1. Ultrasound
Ultrasound (US) is one of the most common techniques used in the initial evaluation of re‐
nal lesions. It is a low cost and easy access technique and it also allows avoiding the expo‐
sure to ionizing radiation and the use of contrast (Figure 1).
Figure 1. Solid mass in right upper kidney (5 x 3.7 cm).
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Although it is an observer-dependent technique, it allows monitoring renal lesions growth
and distinguish between cystic and solid lesions. Ultrasonographic features of cystic lesions
that allow distinction with malignant lesions or abscesses are:
1. Round morphology, smooth and well-defined walls, separating it from the surrounding
parenchyma.
2. There is a strong posterior wall indicating good transmission through the cyst and en‐
hanced transmission beyond the cyst.
3. Absence of internal echoes. The presence of thickened internal septa, calcifications, or
mural vascularity indicate malignancy.
One of its limitations is the evaluation and characterization of small lesions. Jamis found
that CT detected more renal lesions, especially if they were noncontour deforming. 5% of 2
cm lesions were not detected with CT, an 30% were missed in US. Of lesions under 1 cm,
24% were not detected in TC versus 80% with US [4]. Moreover, given the variability in the
echogenicity of malignant kidney, it can be difficult, in the case of isoechoic images, the
identification and distinction of these lesions.
In recent years it has become increasingly important the use of contrast-enhanced ultra‐
sound (CEUS). Current CEUS consist of intravenously injected microbubbles that increase
the number of reflectors in the vascular space. It has different utilities. It is useful in the dif‐
ferential diagnosis of solid and cystic lesions so as to characterize cystic lesions in benign or
malignant [5]. Solid lesions show early arterial enhancement, normally lower than sur‐
rounding parenchyma. The delayed enhancement varies and after an arterial phase lesions
are isoechoic relative to parenchyma. Often because of intralesional necrosis, there are intra‐
lesional areas without contrast enhancement.
It is of particular interest the characterization of complex cystic lesions. Some studies have
reported a sensitivity and specificity similar to CT [6] [7]. It can be considered a valid alter‐
native to CT and MRI in monitoring these lesions that need prolonged follow [8]. It may also
be useful in detecting small renal masses, improving the accuracy of simple ultrasound,
since it allows to observe changes in the thickness of the cortical pyramidal space, not visible
in simple US.
2.2. CT scan
Computed tomography (CT) is the modality of choice for the diagnosis and study of exten‐
sion of renal carcinoma, with a sensitivity greater than 95% (Figure 2) [9]. In addition, the
development of multidetector CT has allowed an increase in the rate of detection and diag‐
nosis in early stages [10].
For the evaluation of suspicious lesions, it is advisable to have a specific protocol. This
should include a scan without contrast to determine the presence of calcification or fatty tis‐
sue within the tumor, and will serve as baseline study to study if these lesions enhance after
contrast administration.
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Figure 2. CT scan, right renal cell carcinoma.
The three perfusion renal phases defined in CT diagnosis are: corticomedullary phase, neph‐
rographic phase, and renal elimination phase (or excretory phase) [11].
The images in the corticomedullary phase help to identify the lesion and its vascular supply,
being optimal for detecting or excluding tumor invasion of the renal veins [12]. The nephro‐
graphic and elimination phase help detecting renal masses, especially those of small size.
The appearance of renal carcinoma in CT varies depending on the size of the tumor vascula‐
ture, the extent of necrosis or intratumoral cystic changes. Enhancement of a renal lesion
shows that it is hypervascular; this is the most important finding in the evaluation of renal
masses, being a useful parameter in differentiating histological subtypes.
Different groups have shown as clear cell  carcinoma has a higher contrast enhancement
than other  histological  subtypes,  especially  papillary  carcinomas [13].  Zhang et  al  show
that 90% of the clear cell renal carcinoma are hypervascular and heterogeneous (with sol‐
id  hypervascular  foci  and  low  attenuation  foci  by  necrotic  or  cystic  changes).  Seventy
five  % of  papillary  carcinomas  were  hypovascular  and 90% had an uniform pattern  or
peripheral uptake while chromophobe tumors often show a moderate and homogeneous
enhancement [10].
Renal Tumor48
Tumors less than 3 cm sometimes have a smooth contour, they are homogeneous and diffi‐
cult to distinguish from some benign lesions. Renal cystic carcinomas usually have thick‐
ened walls and septa, sometimes with calcification. Three-dimensional CT is important in
staging renal cell carcinoma, with the objective of identifying patients having a resectable tu‐
mor and to define the best therapeutic option. The value of CT is limited to the study of the
perirenal fat. Various criteria have been used to describe the appearance of perirenal fat in‐
filtration. Trabeculation of perirenal fat is not a reliable sign of tumor involvement, and is
found in approximately 50% of patients with localized tumors T1 and T2. It can be caused
by edema, vascular congestion, or prior inflammation [14]. The presence of a nodule uptake
in perirenal fat, is considered the most specific finding of perirenal invasion, with high spe‐
cificity (98%) but low sensitivity (46%) [15].
Helical CT has also been shown to have high accuracy in the diagnosis of renal vein in‐
vasion  with  a  negative  predictive  value  of  97% and a  positive  predictive  value  of  92%
(Figure 3) [16].
Figure 3. Renal cell carcinoma with thrombosis of the inferior cava vein.
The adrenal evaluation is important because if no abnormalities are detected on CT, adrena‐
lectomy can be avoided. CT has a high negative predictive value in the detection of adrenal
involvement by RCC. When the adrenal gland is enlarged, displaced or not displayed an
adrenalectomy should be considered [17].
The study of lymph node is based primarily on its size. It is considered that a lymph node
could be metastatic when its diameter is greater than 1 cm. However this approach has a
limited specificity and sensitivity (between 3 and 43% in different studies) because the size
increase may be due to inflammatory changes.
The nodal enhancement pattern helps differentiate between reactive and malignant lympha‐
denopathy. Metastatic lymph nodes can be enhanced after administration of contrast, espe‐
cially if the primary tumor is highly vascularized.
Finally, given that CT plays an important role in detecting distant disease, it is necessary to
conduct a study of the chest and abdomen in the staging of metastatic disease.
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2.3. Magnetic resonance imaging
Magnetic resonance imaging (MRI) is useful when computed tomography cannot be per‐
formed, but it has not proved to be superior to CT in the detection or characterization of
renal masses. The study should include T1 and T2 sequences and opposed-phase images
to  detect  intratumoral  fat.  Dynamic  study after  paramagnetic  contrast  administration  is
essential.
Both CT and MRI have high reliability in delineating the extent of intratumoral thrombus,
since it could change the surgical approach. However, MRI is more sensitive than CT to dif‐
ferentiate between tumoral and non-tumoral thrombus. The tumoral thrombus is heteroge‐
neous or hyperintense on T2-weighted images, with marked enhancement on the
postcontrast images, and, sometimes, it is seen the continuity with the renal tumor. The tu‐
mor thrombus is hypointense, not homogeneous and and does not enhance after contrast
administration [18].
Also, as discussed below, MRI can help us to distinguish between different histological sub‐
types of renal cell carcinoma (RCC), and between these ones and benign tumors such as on‐
cocytomas and angiomyolipomas.
Clear cell RCC usually shows a signal intensity similar to that of the renal parenchyma on
T1-weighted images and it´s high intensity on T2-weighted images (Figure 4). Central ne‐
crosis is common, and it is typically seen as a homogeneus hypointense area in the center of
the mass on T1-weighted images, and hyperintense, rarely hypointense, on T2-weighted im‐
ages [19]. If intratumoral hemorrhage occurs, the appearance of this will depend on the de‐
gree of degradation of its components. A hypointense ring, or pseudocapsule, is sometimes
seen on both T1 and T2-weighted images, and is due to compression of the adjacent renal
parenchyma by the tumor growth. Breakage of this pseudocapsule correlates with advanced
stage and higher nuclear grade [20]. This histological subtype tends to be hypervascular,
with heterogeneous enhancement during the arterial phase. You can also appreciate renal
vein thrombus in more aggressive and advanced tumors. They can also be predominantly
cystic, with only a few areas of solid component [21].
The type I papillary RCC is characterized by a homogeneous hyposignal on T2-weighted
images, with homogeneous low-level enhancement after contrast administration [22]. Some‐
times they show necrosis and hemorrhage. Type II papillary RCC have a more complex ap‐
pearance, with hemorrhage and necrosis. It is common to see a hemorrhagic cystic mass
with enhancing papillary projections at the periphery. In both types is frequent the presence
of a fibrous capsule [23].
Chromophobe RCC may show cystic changes within a solid mass. It is not common the
presence of necrotic foci, even in large tumors. Its appearance on MR can be identical to
those of clear cell RCC [23].
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Figure 4. Clear cell RCC. Heterogeneous tumor with focal posterior bleeding. T2 (left side) and T1 sequence (right
side) with fast gradient contrast, showing renal vein invasion. Courtesy Dr. Armesto-Pérez.
The MR Imaging appearance of oncocytomas is variable and nonspecific. They are typically
spherical and well-defined masses with hyposignal on T1-weighted images and hypersignal
on T2-weighted images, in most cases. The central scar, when present, has a stellate appear‐
ance with low signal intensity on T1-weighted images and high signal intensity on T2-
weighted images, and it may show delayed enhancement after contrast administration.
Sometimes are surrounded by a well-defined hypointense capsule [24].
Angiomyolipoma with a predominant fatty component is isointense relative to fat on all MR
Imaging sequences and its signal intensity is higher than that of the renal parenchyma on
T1-weighted images. Fat-suppression sequences are also useful. Lipid-poor angiomyolipo‐
mas are difficult to distinguish from clear cell RCC with current imaging methods, so may
occasionally be required histopathological evaluation to establish the correct diagnosis [21].
Diffusion-weighted imaging may be useful in differentiating between RCC and oncocytoma
and in the characterization of the different histological subtypes of RCC. Angiomyolipoma,
due to the presence of fat, can give false positives, but it is characterized through conven‐
tional sequences [25] [26].
The whole-body MRI, at present, is positioning itself as one of the techniques of choice for
evaluation of bone marrow in patients with suspected bone metastases with a sensitivity /
specificity (> 90%) higher than the radiology conventional CT and bone scans, and similar to
PET-CT (Figure 5) [27].
Complement the study with diffusion-weighted imaging, besides allowing a faster interpre‐
tation and greater detection of subtle findings could add specificity to the study [28]. This is
particularly relevant with the progressive increased use of new anti tumor drugs in which
this technique may allow better assessment of tumor response [29].
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Figure 5. Whole body MRI. Bone, lung and liver metastases. Courtesy Dr. Armesto-Pérez.
2.4. Bone scan
Bone metastases in RCC is reported in 17-37% of patients and its early identification may have
prognosis importance because its early intervention leads to significant reduction in patient
morbidity. Bone scintigraphy is a very useful tool in diagnosis of bone metastases when those
lesions have sufficient osteoblastic reaction (Figure 6). However, bone metastases in RCC usu‐
ally appear as large expansive lytic lesions, most commonly in the axial skeleton and are poorly
visualized in bone scintigraphy [30], showing variable uptake, with a sensitivity between
10-60% in the diagnosis of this metastases in preselected patients with RCC and high probabili‐
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ty of skeletal involvement with underestimation of the extension of the extension of the meta‐
static involvement, being clearly inferior to other techniques such magnetic resonance imaging
or PET scan [31]. Because most bone metastases are symptomatic, most of authors recommend
the use of bone scintigraphy only in symptomatic patients with or without raised level of alka‐
line phosphatase [32,33], although others believe that because its poor sensitivity, the routine
use of bone scintigraphy in RCC needs to be questioned [34,35].
Figure 6. Bone scan of a patient with renal cancer showing metastases in the right tibia, left femur, pelvis and rib
cage.
2.5. PET
We can study the PET role of in RCC from three points of view: localized disease, extensive
disease and monitoring treatment response.
Localized disease: Most of publications in this patient subset have been made in a retrospec‐
tive way and many of them studied patients from the PET archive and not from the popula‐
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tion of patients with a suspicious kidney mass. More recently we have knows the result of a
prospective study that examined 18 patients with renal lesions suspicious for malignancy di‐
agnosed on CT, MRI or ultrasound [36]. In all patients, a FDG-PET/CT was made and diag‐
nosis of malignancy was suspected when intensity on PET was greater than intensity in the
renal parenchyma and it was different from the physiological excretion in the collecting sys‐
tem. Patients underwent nephrectomy or surgical resection of the renal mass with the re‐
spective histological analysis. PET showed a sensitivity of 46,6% and a specificity of 66,6%.
The median diameter and Furhman grade of FDG positive malignant lesions were signifi‐
cantly higher than in FDG-negative malignant lesions (p< 0,05). It is difficult to draw conclu‐
sions with a study involving a sample of patients so small, but we can see that about half of
the patients could not be diagnosed by PET, so probably we will have to expect better re‐
sults with this diagnostic technique before introducing it as part of a routine preoperative
diagnosis of RCC. A modification of the technique is the immunological PET, using 124I-
cG250 (chimeric girentuximab labeled with 124I) because cG250 functions as an epitope of
CAIX, a transmembrane enzyme that is almost universally expressed in clear cells RCC cells.
With this modality has been observed a 94% sensitivity and 100% specificity, with positive
and negative predictive values of 100% and 90% respectively, in a population of 26 patients
with renal masses suspicious for malignancy [37].
Extensive disease: Although in the metastatic RCC PET has better sensitivity (63-100%) than
in localized disease, some authors believe that FDG-PET currently appears to be too unrelia‐
ble to recommend is routine use in the staging of RCC, because it is less sensitive than radio‐
logical imaging for retroperitoneal lymphadenopathy and bone or lung metastases [38].
However, this technique may have a place detecting recurrence and probably an associated
prognostic value (Figure 7). In a recent study, the authors found a sensitivity and specificity
of 81% and 71% respectively, for FDG-PET in the diagnosis of recurrence, with correct diag‐
nosis in all cases of intra-abdominal (lymph nodes, local recurrence and adrenal glands) and
bone recurrence, with a clear trend for better 5-year survival in PET-negative patients com‐
pared with PET-positive patients: 83% versus 46% respectively [39].
Monitoring treatment response: Systemic treatment in metastatic RCC is represented for
multikinase inhibitors like sorafenib and sunitinib. This drugs are actives because its capaci‐
ty of inhibition on the tyrosine kinase receptor VEGF and the platelet-derived growth factor
receptor, in the endothelial cells and pericytes. Because expression of Glut (a downstream
product of HIF transcriptional activity), it is conceivable that intensity of FDG uptake may
be reflective of the magnitude of the entire pathway [40]. In other words, the variable inten‐
sity of FDG-PET in RCC may reflect variable strength of the HIF signaling pathway. Kayani
et al. studied prospectively 44 treatment naive metastatic RCC. A basal (pretreatment) FDG-
PET was made and them repeated it at 4 and 16 weeks of treatment. The most intense lesion
of each patient (SUV > 2.5) was used as the index lesion and they defined metabolic re‐
sponse as a decrease of > 20% in SUV and metabolic disease progression as an increase of
>20 % or development of new metastatic lesions. In the first comparison (after 4 treatment
weeks) they found a metabolic response in 24 (57%) patients but without correlation with
the PFS or overall survival. In the second comparison (16 treatment weeks), 12 (28%) pa‐
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tients had metabolic disease progression, which correlated with decreased OS and PFS 8HR:
5.96 [95% CI: 2.43-19-02] and 12,13 [95% CI:3,72-46,51]), respectively [41]. With these results,
we can conclude that the FDG-PET probably may be more useful in diagnosing tumor pro‐
gression than treatment response. Another point that deserves to be examined is whether
the cutoff of 20% is appropriate to differentiate responders from those who do not.
Figure 7. PET scan showing loco-regional recurrence (red arrows), in a patient with a previous left nephrectomy.
3. New techniques in imaging of renal tumors
The introduction of functional imaging techniques have allowed us to study in vivo physio‐
logical processes of tissues and tumors. Techniques such as computed tomography (CT) or
magnetic resonance (MR) allow us to study tumor perfusion (angiogenesis). Positron emis‐
sion tomography (PET) scan or spectroscopy RM is useful in the evaluation of tumor metab‐
olism while difusion RM allows the study of the diffusion of water molecules through the
diffusion sequences (cellularity) to assess hypoxia phenomena or changes in the lymph no‐
des function. All these techniques can obtain information on the tumor microenvironment,
including levels of oxygenation, tumor cell proliferation or vascularization and open a dif‐
ferent dimension in the study of patients: diagnosis, staging, treatment planning, evaluation
of response or follow-up [42] [43].
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For example, dynamic techniques (MRI or CT) seem most appropriate for assessing antivas‐
cular drug response or acting in the VEGF/ PDGFR pathway, such as bevacizumab, whose
mechanism of action appears to focus on normalization of tumor vascularization [Jain 2005],
while the PET appears to do better in the case of drugs such as cetuximab, acting in the
EGFR pathway [44] [45] [46].
3.1. Perfusion-CT
Perfusion CT is based on the temporal change of the attenuation of tissues after intravenous
administration of iodinated contrast. This study consists of two phases. The first phase lasts
between 40 and 60 seconds in which the enhancement is mainly due to the contrast distribu‐
tion in the intravascular space and its rapid passage to the extracellular space. This phase
requires high temporal resolution (one acquisition per second). In the second phase the con‐
trast enhancement depends on its distribution between intra-and extravascular compart‐
ments. In this period the acquisition in more spaced and lasts between 2 and 5 minutes [47]
[48] [49,50].
This functional technique can be used to measure a number of parameters including vascu‐
lar blood flow, blood volume, mean transit time, peak enhancement, time to peak enhance‐
ment and capillary permeability. Several studies have validated functional CT data as a
biomarker of angiogenesis [47] [51]. There is growing interest on the use of CT perfusion in
oncology with multiple applications that may be helpful: differential diagnosis between be‐
nign and malignant neoplasms, identifying tumors of unknown origin (with impaired liver
perfusion with occult metastatic disease), definition of prognosis (with best response in tu‐
mors with more perfusion), monitoring response to treatment and development of new
drugs (Figures 8 and 9) [50]. The technique is being applied in multiple tumor types: head
and neck, lung, liver, pancreas, colorectal cancer, lymphoma and prostate.
Figure 8. Renal Cancer. Liver metastasis treated with temsirolimus. Axial CT image (A) and blood volume (B) and
blood flow (C) parametric maps show low perfusion parameters in metastasis. Courtesy Dr. García Figueiras.
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Figure 9. Renal Cancer with diffuse metastatic disease (black arrows) in a 58 year-old female patient. Pre-therapy (left
column) and 10 days post-sunitinib (right column). Axial CT images, blood flow (BF) parametric maps, and curves time-
density show a partial response with disappearance of some metastatic foci, necrotic changes in many of them, a
change in enhancement curve (white arrows) and a BF decrease by 95% in tumor. Courtesy Dr. García Figueiras.
3.2. DCE-MRI
Other functional imaging techniques not specifically focused on the study of angiogenesis,
such as diffusion MRI, enabling the study of tumor cellularity and having quantitative pa‐
rameters such as the apparent diffusion coefficient (ADC). Thus, tumors with high cellulari‐
ty show low ADC [52] [53]. Moreover, since tumor response is associated with destruction
of tumor cells, it is generally associated with increased ADC tumor lesions. The diffusion
thus evaluate the apoptotic and necrotic effect but not angiogenesis, main target of new
drugs.
Preliminary studies have shown significant changes very early in the flow, blood volume
and perfusion with tumor therapy. There is a relationship between changes in Ktrans, Kep
and the area under the curve and the response in different tumors, showing a very marked
functional changes in the vascular supply to the tumor [54] [55]. Therefore these techniques
could be worth to select those patients who will respond to drugs with an early evaluation
of the response using functional imaging.
In a subgroup of patients enrolled in the phase II study discontinuation of sorafenib, DCE-
MRI was performed before and after initiation of treatment. Radiological response by RE‐
CIST criteria was observed in 4/17 patients (ORR 24%), and time to progression was 12.9
months. Ktrans decreased significantly during treatment with sorafenib (60.3% decrease,
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95% CI 46.1 to 74.6%). The percentage decrease in Ktrans and change in tumor size was sig‐
nificantly associated with progression-free survival (p = 0.01 and 0.05, respectively).
3.3. PET
Finally, molecular techniques such as PET show a limited role in the study of metastatic re‐
nal cancer, since this tumor usually has a low activity of glucose metabolism (pathway as‐
sessed by 18F-fluorodeoxyglucose, the most widely used radiotracer). Only in cases where
the tumor shows an increased metabolism of glucose, PET may be useful in the assessment
of the disease and its response to therapy. Other radiotracers that allow the study of impor‐
tant characteristics such as tumor hypoxia, cell proliferation or angiogenesis itself, are still
under evaluation and implementation in clinical practice [56]. In an experimentally way it is
evaluating the introduction of functional imaging techniques in clinical studies, to develop
translational research in oncology imaging applications. In a NCI trial, Dr. Hoffman (Uni‐
versity of Utah) is using DCE-MRI and various types of PET (H2150-PET, FDG-PET, FDL-
PET) in monitoring response to multi-targeted treatment in renal cancer patients.
4. Response evaluation
4.1. Evaluation of response: Antiangiogenics and mTOR inhibitors
We must consider several issues when assessing the therapeutic response of tumors. The
morphological assessment with quantification of changes in size used in the RECIST criteria
("Criteria in Solid Tumors Response") has been our main concern when assessing tumor re‐
sponse [2]. This approach seems true for the use of cytotoxic drugs. However, this assess‐
ment is limited, since the macroscopic changes take time to become evident, often are not
specific and do not provide information on the physiological and molecular component of
tumors [42].
Advances in the field of oncology have led to the development of new drugs in renal cancer
as sunitinib, sorafenib, pazopanib, tivoaznib, axitinib, temsirolimus, everolimus and bevaci‐
zumab [46]. These drugs (mainly cytostatic) cause little change in lesion size. Therefore, RE‐
CIST criteria are not entirely suitable for assessing tumor response, and proper techniques
will vary according to the mechanism of action of the drug.
The recent emergence of techniques for the functional study of angiogenesis, such as perfu‐
sion CT or dynamic MRI allow obtaining quantitative parameters (blood volume, blood
flow mean transit time, ktrans Ve, etc.) and would open a interesting field for assessing tu‐
mor response in a more objective [57] [58] [59]. This could open the door to the development
of a strategy based on the image for the selection of patients to be treated with antiangiogen‐
ic therapies. However, each of these techniques has advantages and disadvantages. Thus,
CT perfusion shows the drawback of radiation necessary for conducting the studies, where‐
as in the case of dynamic MRI the analysis of the results is much more complex.
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The functional  and molecular  imaging techniques  could offer  clear  opportunities  in  the
study of  renal  tumors,  but  nevertheless,  we must  not  forget  that,  for  validation as  bio‐
markers,  would  require  completing  a  qualification  and  validation  process,  which
would  pass  through  standardization  in  the  collection  and  analysis  of  the  images  and
the  correlation  of  the  parameters  obtained  with  patient  outcomes.  Once  this  is  ach‐
ieved,  functional-molecular  techniques,  especially  perfusion  CT,  could  become  promis‐
ing  tools  in  the  selection  of  patients  for  targeted  drug  therapy  and  the  assessment  of
the response [57]  [58].
5. Criterios RECIST/MASS/CHOI
Classically, oncology response evaluation is based on comparison of pre and post-treatment
tumor volume by studying changes in the diameter of the tumors. RECIST criteria in its
original version and its 2009 Update 1.1 are applied routinely in oncology practice [2]. How‐
ever, it is recognized that the response evaluation focused exclusively on size changes have
important limitations, including the importance of excluding changes in tumor metabolism
or not considering the appearance of necrosis or fibrosis as a factor which may be related to
response to treatment. Furthermore, the introduction of new drugs creates the need for a
different evaluation of the tumor and treatment response [46].
The limitations  of  traditional  approaches,  as  the  criteria  of  the  World Health  Organiza‐
tion (WHO) or Response Evaluation Criteria in Solid Tumors (RECIST) in the evaluation
of targeted therapies have been widely documented [64] [65] [57].  Therapies that act  on
tumor vascularity  may have underestimated clinical  benefit  by tumor size  change since
their  mechanism  of  action  (more  cytostatic  that  cytotoxic),  produces  more  stabilization
than tumoral responses.
Without abandoning the use of size criteria as a key element in the assessment of patients
with metastatic renal cancer, some authors have attempted to obtain early information (EP‐
TIC, Early English Post-herapy Imaging Changes) [66] on the prognosis of patients treated
with therapy acting at the VEGF pathway. In this regard, it was demonstrated that a 10%
decrease in the sum of the largest diameters of the lesions in the first control, provides infor‐
mation on the subsequent course of patients. Using only tumor size as endpoint criterion
would leave aside the use of IV contrast.
Subsequently it was observed a relationship between the degree of tumor enhancement be‐
fore therapy and the likelihood of response (being higher in those tumors with greater pre‐
treatment enhancement). Many of these new drugs induce tumor necrosis, causing a
dramatic drop in the enhancement of metastatic lesions in the post-therapy evaluation [67].
Based on these observations and on previous experience with gastrointestinal stromal tu‐
mors treated with imatinib, a set of tumor response criteria based on changes in size and / or
density tumor was established: Choi criteria, modified Choi criteria, MASS criteria and
SACT criteria (Table 1) [56].
Imagen Thecniques in Renal-Cell Carcinoma
http://dx.doi.org/10.5772/54190
59
Criterio Targetedlesions
Complete
response
Partial
response Stable disease Progressive disease
RECIST version
1.1 (2)
Tumor size
10 mm by
CT scan
Disappearance of
all lesions
Decrease in
size 30%
Does not meet
criteria for PR or
PD
Increase in tumor size
20% (the sum must also
demonstrate an
absolute increase of at
least 5 mm)
Tumor size
15 mm by
chest X-ray
No new lesions No new lesions New lesions
Maximum
of 5 target
lesions
No PD of non-
target lesions
EPTIC (Early
Posttherapy
Imaging
Changes) (60)
Establishing the prognosis depending on the % size decrease after antiangiogenic therapy
Decreased size ≥ 10%= good prognosis.
Choi Criteria
(61) (3)
Tumor size
15 mm
Disappearance of
all lesions
A decrease in
size 10% or a
decrease in
tumor
attenuation
(HU) 15% on
CT
Does not meet
criteria for CR, PR
or PD
Increase in tumor size
10% and does not meet
criteria of PR by tumor
attenuation
Maximum
of 10
target
lesions
No new lesions
No new lesions
, no obvious
progression of
non-
measurable
disease
No symptomatic
deterioration
attributed to PD
New lesions
Modified Choi
Criteria (62)
Tumor size
15 mm
Disappearance of
all lesions
A decrease in
size 10% and a
decrease in
tumor
attenuation
(HU) 15% on
CT
Does not meet
criteria for CR, PR
or PD
Increase in tumor size
10% and does not meet
criteria of PR by tumor
attenuation
Maximum
of 10
target
lesions
No new lesions
No new lesions
, no obvious
progression of
non-
measurable
disease
No symptomatic
deterioration
attributed to PD
New lesions
Renal Tumor60
Criterio Targetedlesions
Complete
response
Partial
response Stable disease Progressive disease
SCAT Criteria
(29)
Tumor size
10 mm
Decrease in
tumor size
20%
Does not meet
criteria for PR or
PD
Increase in tumor size
20%
Maximum
of 10
target
lesions
Decrease in
tumor size10%
and _half of
the non-lung
target lesions
with 20 HU
decreased
mean
attenuation
New metastases, marked
central fill-inc of a target
lesion or new
enhancement in a
homogeneously
hypoattenuating
nonenhancing mass
MASS criteria
(63)
Favorable response.
No new lesions and any of the
following:
1. Decrease in tumor size 20 %
2. One or more predominantly solid
enhancing lesions with marked
central necrosis or marked
decreased attenuation ( 40 UH)
Does not meet
criteria for
favorable or
unfavorable
response
Any of the following:
1. Increase in tumor size
of 20 % in the absence
of marked central
necrosis or marked
decreased attenuation
2. New metastases,
marked central fill-in, or
new enhancement of a
previously
homogeneously
hypoattenuating
nonenhancing mass
Functional
and molecular
image.
No response criteria defined
CR: complete response. PR: partial response. NC: no changes. PD: progressive disease. RECIST: Response Evaluation
Criteria in Solid Tumors. CT: computed tomography. SACT: criteria size and attenuation CT (SACT) criteria. HU:
Hounsfield Unit.
CR: complete response. PR: partial response. NC: no changes. PD: progressive disease. RECIST: Response Evaluation Cri‐
teria in Solid Tumors. CT: computed tomography. SACT: criteria size and attenuation CT (SACT) criteria. HU: Hounsfield
Unit.
Table 1. CT-based criteria for response evaluation of targeted therapies in renal cell carcinoma.
Each of these criteria has a number of advantages compared to RECIST, but some limita‐
tions. So Choi criteria, based on the change in size or tumor density on CT (% change in the
measured attenuation value at UH), show little advantage over RECIST when establishing
the possibility of a long-term response. Furthermore, these show a different utility criteria
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depending on the type of drug tested, being most useful in the case of sorafenib (which
tends to cause more degree of necrosis in lesions) than for sunitinib.
Modified Choi criteria evaluate existing changes in both size and tumor density after treat‐
ment. These criteria could differentiate those patients at risk of disease progression, but
shows a tendency to classify patients as responders.
SACT criteria (Size and Attenuation CT) differ from the modified Choi criteria that estab‐
lish an absolute value of change in tumor density (> 20 UH) rather than a % of change. These
criteria are more reliable in the case of low attenuation pre-therapy lesions, in which it is
easier to obtain a percentage decrease in density.
Finally, the MASS criteria (Morphology, Attenuation, Size, and Structure) include morpho‐
logical and structural elements regardless of the size and density of lesions. These criteria
are intended to take into account the extensive necrotic changes frequently associated with
tumor response to these drugs [63].
However, both SACT as MASS criteria are complicated and basically useful in differentiat‐
ing patients with a long progression-free survival (> 250 days) of those showing a rapid pro‐
gression (<250 days). Overall, we consider that in all these criteria contrast enhancement of
lesions plays a major role, so that both imaging protocols (volume of contrast acquisition
phase, etc.) or factors such as cardiac function patient can significantly influence the results.
6. Summary
The era of molecular biology have created great expectations on our ability to translate these
discoveries into effective treatments for patients. Over the last decade, there has been an in‐
creasing knowledge about pathophysiological processes that are common to most tumors
including: independence from growth signals, insensitivity to growth-inhibitory signals,
evasion of apoptosis, limitless potential for replication, sustained angiogenesis, and tissue
invasion and metastasis. These major pathways deregulated in cancer have a key role in tu‐
mor development and microenvironment. These features have enabled the emergence of a
wide spectrum of novel oncologic drugs that are designed to target and interfere with spe‐
cific aberrant biological pathways. In general, these agents use different strategies to inter‐
fere with specific biological targets, such as blocking growth factors, receptors, or tyrosine
kinase (TK) action.
The use of new drugs in the treatment of advanced or metastatic kidney cancer, with differ‐
ent mechanisms of action compared to conventional chemotherapy raises new questions.
One of the biggest problems with new drugs are produced in the evaluation of the response,
and the incorporation of new imaging techniques (MRI diffusion, perfusion CT, nuclear
medicine, etc....) in the diagnosis of extension and assessment of efficacy.
In this chapter we have reviewed the main techniques of radiological diagnosis and staging,
the value of new imaging modalities, and discuss the validity of the classical criteria of inter‐
pretation of response.
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